GSK PLC closed 16.09% below its 52-week high of £16.79, which the company achieved on September 9th.

GSK PLC closed 13.35% below its 52-week high of £16.79, which the company reached on September 9th.

The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

GSK supports seasonal flu immunization in the US by shipping FLULAVAL (Influenza Vaccine) and FLUARIX (Influenza Vaccine) in ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

The UK's main stock indexes rose on Wednesday, with investors focusing on a slate of corporate news while awaiting further ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Anant Ambani and Radhika Merchant brought global attention to Indian culture, world leaders, celebrities, and business icons ...

The primary exposure was a first-trimester prescription fill of nitrofurantoin, TMP-SMX, fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin), and β-lactams to treat UTI. Any congenital ...